Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Inmed Pharmaceuticals IN (IN.TO)

Inmed Pharmaceuticals IN (IN.TO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 51,685
  • Shares Outstanding, K 172,284
  • Annual Sales, $ 0 K
  • Annual Income, $ -13,255 K
  • 60-Month Beta 5.93
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.45
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.08
  • Most Recent Earnings -0.02 on 09/30/19
  • Next Earnings Date 02/11/20
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.02
  • Number of Estimates 1
  • High Estimate -0.02
  • Low Estimate -0.02
  • Prior Year -0.02
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.23 +34.78%
on 12/31/19
0.43 -27.91%
on 01/21/20
+0.07 (+29.17%)
since 12/27/19
3-Month
0.23 +34.78%
on 12/31/19
0.43 -27.91%
on 01/21/20
+0.06 (+24.00%)
since 10/29/19
52-Week
0.22 +40.91%
on 08/27/19
0.80 -61.25%
on 02/05/19
-0.24 (-43.64%)
since 01/29/19

Most Recent Stories

More News
InMed Expands on Announcement of Cannabinol (CBN) Therapeutic Leadership with New Website Content and CEO Interview

VANCOUVER , Jan. 21, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical stage biopharmaceutical company developing medications targeting...

IMLFF : 0.2375 (-1.94%)
IN.TO : 0.31 (+3.33%)
InMed First to Advance Cannabinol (CBN) into Therapeutic Clinical Trials

VANCOUVER , Jan. 20, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical stage biopharmaceutical company developing therapeutics targeting...

IMLFF : 0.2375 (-1.94%)
IN.TO : 0.31 (+3.33%)
InMed Pharmaceuticals to Attend and Exhibit at EB2020 World Congress

VANCOUVER , Jan. 16, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or "the Company") (TSX:IN; OTCQX:IMLFF), a clinical stage biopharmaceutical company developing cannabinoid-based medications...

IMLFF : 0.2375 (-1.94%)
IN.TO : 0.31 (+3.33%)
InMed Announces Election of Directors

VANCOUVER , Jan. 10, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX:IN; OTCQX:IMLFF), a clinical stage biopharmaceutical company developing cannabinoid-based medications...

IMLFF : 0.2375 (-1.94%)
IN.TO : 0.31 (+3.33%)
InMed Pharmaceuticals to Present at the Biotech Showcase Conference

VANCOUVER , Jan. 8, 2020 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or "the Company") (TSX:IN; OTCQX:IMLFF), a clinical stage biopharmaceutical company developing cannabinoid-based medications...

IMLFF : 0.2375 (-1.94%)
IN.TO : 0.31 (+3.33%)
InMed Receives Clinical Trial Application Approval for INM-755, a Rare Cannabinoid Formulation Under Development for the Treatment of Epidermolysis Bullosa

VANCOUVER , Dec. 9, 2019 /PRNewswire/ -  InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN; OTCQX: IMLFF), a clinical stage biopharmaceutical company developing cannabinoid-based...

IMLFF : 0.2375 (-1.94%)
IN.TO : 0.31 (+3.33%)
Edison issues update on InMed Pharmaceuticals

LONDON, UK / ACCESSWIRE / November 18, 2019 / InMed Pharmaceuticals (TSX:IN) recently announced that it filed a Clinical Trial Application in the Netherlands for INM-755, which is being developed for epidermolysis...

IMLFF : 0.2375 (-1.94%)
IN.TO : 0.31 (+3.33%)
InMed Pharmaceuticals to Present at the Cowen Conference

VANCOUVER , Nov. 11, 2019 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or "the Company") (TSX:IN; OTCQX:IMLFF), a biopharmaceutical company developing a proprietary biosynthesis manufacturing...

IMLFF : 0.2375 (-1.94%)
IN.TO : 0.31 (+3.33%)
InMed Pharmaceuticals Reports First Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update

VANCOUVER , Nov. 8, 2019 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN; OTCQX: IMLFF), a biopharmaceutical company developing a proprietary biosynthesis manufacturing...

IMLFF : 0.2375 (-1.94%)
IN.TO : 0.31 (+3.33%)
InMed Submits Clinical Trial Application to Evaluate INM-755 in Phase 1 Trial

VANCOUVER , Nov. 5, 2019 /PRNewswire/ -  InMed Pharmaceuticals Inc. ("InMed" or the "Company") (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application ("CTA") in...

IMLFF : 0.2375 (-1.94%)
IN.TO : 0.31 (+3.33%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Key Turning Points

2nd Resistance Point 0.33
1st Resistance Point 0.32
Last Price 0.31
1st Support Level 0.29
2nd Support Level 0.27

See More

52-Week High 0.80
Fibonacci 61.8% 0.58
Fibonacci 50% 0.51
Fibonacci 38.2% 0.44
Last Price 0.31
52-Week Low 0.22

See More

Business Summary

InMed Pharmaceuticals Inc is a Canada based pre-clinical stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based therapies combined with drug delivery systems. It is focused on the treatment of diseases including pain and inflammation, dermatology,...

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar